Article
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Cancer discovery - 1 Apr 2015
Ahronian Leanne G, Sennott Erin M, Van Allen Eliezer M, Wagle Nikhil, Kwak Eunice L, Faris Jason E, Godfrey Jason T, Nishimura Koki, Lynch Kerry D, Mermel Craig H, Lockerman Elizabeth L, Kalsy Anuj, Gurski Joseph M, Bahl Samira, Anderka Kristin, Green Lisa M, Lennon Niall J, Huynh Tiffany G, Mino-Kenudson Mari, Getz Gad, Dias-Santagata Dora, Iafrate A John, Engelman Jeffrey A, Garraway Levi A, Corcoran Ryan B
Abstract excerpt
UNLABELLED: BRAF mutations occur in approximately 10% of colorectal cancers. Although RAF inhibitor monotherapy is highly effective in BRAF-mutant melanoma, response rates in BRAF-mutant colorectal cancer are poor. Recent clinical trials of combined RAF/EGFR or RAF/MEK inhibition have produced improved efficacy, but patients ultimately develop resistance. To identify molecular alterations driving clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.